Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine

[Business Wire] – Pfizer Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for bivalent recombinant LP2086 (r Read more on this. Pfizer . . . → Read More: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine Similar Articles: Pfizer Inc (NYSE:PFE) | Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14